Published in final edited form as:

Curr Opin Pediatr. 2018 June ; 30(3): 332–337. doi:10.1097/MOP.0000000000000623.

Lymphatic Dysfunction in Critical Illness

Edmund Burke, MD and Sanjeev A. Datar, MD, PhD*

University of California, San Francisco Benioff Children's Hospital, Division of Critical Care Medicine, 513 Parnassus Avenue, HSE1418, Box 1346, San Francisco, CA 94127

Abstract

Purpose of review—The essential role of the lymphatic system in fluid homeostasis, nutrient transport, and immune trafficking is well-recognized, however there is limited understanding of the mechanisms that regulate lymphatic function, particularly in the setting of critical illness. The lymphatics likely affect disease severity and progression in every condition, from severe systemic inflammatory states to respiratory failure. Here, we review structural and functional disorders of the lymphatic system, both congenital and acquired, as they relate to care of the pediatric patient in the intensive care setting, including novel areas of research into medical and procedural therapeutic interventions.

Recent findings—The mainstay of current therapies for congenital and acquired lymphatic abnormalities has involved non-specific medical management or surgical procedures to obstruct or divert lymphatic flow. With the development of dynamic contrast-enhanced magnetic resonance lymphangiography, image-directed percutaneous intervention may largely replace surgery. Because of new insights into the mechanisms that regulate lymphatic biology, pharmacologic inhibitors of mTOR and leukotriene B4 signaling are each in Phase II clinical trials to treat abnormal lymphatic structure and function, respectively.

Summary—As our understanding of normal lymphatic biology continues to advance, we will be able to develop novel strategies to support and augment lymphatic function during critical illness and through convalescence.

Keywords

image-directed percutaneous embolization; chylothorax; plastic bronchitis; lymphatic dysfunction in critical illness; sirolimus; ubenimex

Introduction

References to the lymphatic system have dotted the medical literature since the 4th century BC, when Aristotle described “fibers which take position between the blood vessels and nerves and which contain a colorless liquid” [1]. Hippocrates’ exposition “On glands” similarly reported a system of vessels and nodes which “attract and receive fluid” in health, but in illness, when overwhelmed with humors, become inflamed “in sympathy with the

*corresponding author, sanjeev.datar@ucsf.edu.

Conflicts of Interest

The authors have no conflicts to disclose.

body” [2]. Subsequent writers documented milky vessels coursing through the mesentery, with Gasparo Aselli being credited in 1622 with describing prominent “lacteal arteries” during vivisection of dogs that were well-fed but not those that were starved [1].

By no later than the 17th century, then, investigators had described or foreshadowed the three major functions of the lymphatic system as it is understood today: the homeostasis of fluid and solute balance between the interstitial and intravascular spaces; the absorption and transport from the viscera of fats; and the surveillance of the body for infection and its role as a locus for immune response. Yet, despite its early recognition and its presence in nearly every vascular tissue, the “other” circulatory system has garnered a fraction of the attention and research afforded the vascular system, a state of neglect historically blamed on challenges in visualizing its components *in vivo* [3].

The 21st century, however, has heralded a renaissance in lymphatic investigation, a boom aided primarily by advances in techniques that allow lymphatic imaging and by improved understanding of the molecular and genetic determinants of lymphatic structure and function, areas of progress which together offer both diagnostic and therapeutic advances. Despite this progress, it is still not well understood what role the lymphatics play in critical illness. It is known that the lymphatic vasculature is broadly distributed over the entire body [4], including the central nervous system [5,6] which until very recently was considered a site of immune privilege [7]. The lymphatics likely affect disease severity and progression in every condition that is treated in the intensive care unit (ICU), including in patients with congenital heart disease, acute pancreatitis, respiratory failure, neurologic deterioration, and after solid organ transplantation and burn injury. In this article, we will review structural and functional disorders of the lymphatic system, both congenital and acquired, as they relate to care of the pediatric patient in the intensive care setting, including novel areas of research into medical and procedural therapeutic interventions. This review will not cover in any detail the genetic determinants of lymphangiogenesis or the lymphatic disorders that result from syndromes or altered developmental programs, which have been extensively covered elsewhere [8–12].

Congenital and Acquired Disorders of the Lymphatic System in the Cardiac Patient

The cardiac patient may manifest disorders of the lymphatic system due to chronic exposure to the abnormal physiology of single ventricle palliation; acutely, after cardiothoracic surgery; before surgical repair or palliation due to developmental lymphatic abnormalities associated with abnormal fetal physiology; or possibly from primary lymphatic dysgenesis as part of an underlying genetic disorder affecting both cardiac and lymphatic development.

Noting the strong association of nuchal translucency (a finding caused by edema related to lymphatic insufficiency) with a wide variety of cardiac defects in both aneuploid and euploid patients, Burger et al identified 15 candidate genes that contribute to both congenital heart disease and lymphatic abnormalities in a mouse model [13], and while much remains to be elucidated from a genetic perspective about the related development of these two systems in

humans, it may be that the cardiac patient is abnormal from a lymphatic standpoint from the earliest phases of development.

More is understood about the effects of abnormal fetal physiology on the lymphatic system, with perhaps the best-studied model being hypoplastic left heart syndrome with intact atrial septum. Comparing histopathology specimens in HLHS patients with and without intact atrial septum, Rychik et al reported massively dilated lymphatics in the former group [14], presumably related to the impediment to pulmonary venous drainage, similar to an earlier report from 1986 by Moerman et al who described congenital pulmonary cystic lymphangiectasis due to premature closure of the foramen ovale in patients with severe aortic stenosis [15]. It is not only patients with obstruction to pulmonary venous return in fetal life who may be at risk for congenital lymphatic dysplasia. In a surgical sheep model of increased pulmonary blood flow from our group, late gestation lambs underwent placement of an aorto-pulmonary graft, and after delivery, cannulation of the draining vessel of the pulmonary lymphatics. In this model, chronically increased pulmonary blood flow was associated with impaired pulmonary lymph flow, dilated pulmonary lymphatics, and altered expression of genes known to be important for lymphatic growth and development [16]. Taken together, these studies suggest that many cardiac patients may already have abnormal lymphatic structure and/or function at the time of birth.

A frequently encountered lymphatic issue in the ICU is chylothorax, or accumulation of lymph fluid in the thorax, an entity which may be either congenital or acquired. Congenital chylothorax may be due congenital lymphatic malformations such as lymphangiomatosis, lymphangiectasia or atresia of the thoracic duct, or may be found in association with a wide range of syndromes, such as Down, Noonan, Turner and Gorham-Stout syndromes, with or without gross lymphatic disorganization [17]. As a congenital disease, chylothorax carries a high mortality, with death rates reported to be as high as 33% [18]. Chylothorax is also a fairly common complication after cardiothoracic surgery with a reported incident of 2%-5% [19]; a recent study of the Pediatric Health Information System database noted that the highest incidence was seen after superior and inferior cavopulmonary anastomosis surgeries as part of staged palliation in single ventricle patients, arterial switch operation, and heart transplant [20]. The potential effects of postoperative chylous effusion are myriad, with the same study reporting an increase in in-hospital mortality (OR 2.3), as well as increased length of stay and cost of hospitalization. Accumulation of fluid in the thorax may lead to respiratory failure and has been associated with increased time of postoperative mechanical ventilation [21], while other effects are related to impairment of the various functions of the lymphatic system as elaborated above. Indeed, long term chylothorax may lead to muscle wasting, weight loss and other signs of compromised nutrition [22], as well as immunocompromise due to loss of immunoglobulin and lymphocytes [23].

Chylothorax has been long recognized as a complication after surgery, but advances in imaging have allowed a greater understanding of its varied causes. Using dynamic contrast-enhanced magnetic resonance lymphangiography (DCMRL), a recently described technique based on intranodal injection of a gadolinium-based contrast [24,25], Savla et al evaluated 25 patients with postoperative chylothorax [26] and reported three distinct etiologies. Only two patients were identified as having traumatic leak, in both cases in a tributary to the

thoracic duct, while 14 were deemed to have pulmonary lymphatic perfusion syndrome (PLPS) and 9 to have central lymphatic flow disorder (CLFD), two complex disorders of lymphatic flow that have been described as imaging has allowed their identification. PLPS was first reported in the post-Fontan population and is marked by centrifugal flow from the thoracic duct toward peribronchial vessels and the lung parenchyma, a reversal of the typical centripetal flow from the periphery towards the central duct. CLFD, meanwhile, is a disorder marked by reduced or absent central lymphatic flow, effusions in multiple compartments, and dermal reflux of lymph through collateral vessels in the abdominal wall. The central flow abnormality may be related to congenital absence of the thoracic duct, anatomic thoracic duct outlet obstruction or previous thoracic duct ligation.

Management of chylous effusion includes both medical and interventional approaches and an optimal treatment algorithm will evolve only with time. Successful percutaneous approaches to target implicated lymphatic vessels have been described [27,28], with the goal of directing lymph flow away from the intrathoracic space, but it is clear that patient factors play a crucial role. In the above paper, Savla et al reported that patients in the PLPS and traumatic injury groups responded well to percutaneous intervention in the form of selective or total thoracic duct embolization, but in contrast, patients in the CLFD group had poor outcomes, with most dying [26]. Image-directed percutaneous intervention may have largely replaced surgical thoracic duct ligation and pleurodesis [26], but until there is more cumulative experience with lymphatic imaging and intervention, the initial treatment for most patients will continue to be medical. An exhaustive review of medical treatment is outside of the scope of this review but effective treatment of postoperative chylothorax may include NPO status, reduction in long chain triglycerides and use of the somatostatin analogue octreotide [29,30]. In the congenital chylothorax population, successful medical management has been reported with propranolol [31], sirolimus [32], an inhibitor of mammalian target of rapamycin (mTOR), and oral sildenafil [33].

Many of the same anatomic and physiologic perturbations of the lymphatic system that lead to chylothorax in the acute period after cardiothoracic surgery may contribute to plastic bronchitis in the post-Fontan cardiac patient. Plastic bronchitis is caused by the exudation of proteinaceous material and cells from the lymph into the airway, leading to formation of tell-tale “casts” in the lower airways with potentially severe respiratory compromise. It is a rare complication of the Fontan circulation, with an estimated prevalence in that group of 4% [34], but one with a high mortality, reported between 12 and 50% [35]. Effective interventional therapies have included procedures aimed at lowering central venous pressure and improving lymphatic egress into the venous system [36] as well as heart transplantation [37], while successful medical management has been described with steroids [38], mucolytic therapy [39], and sildenafil [40]. More recently, the same advances in lymphatic imaging and intervention have opened a promising avenue of treatment. Dori et al described their experience with 17 patients undergoing thoracic duct embolization or placement of covered stents to exclude centrifugal flow and reported symptomatic improvement in 88% of their cohort [35].

Lymphatic Malformations and Airway Compromise

Congenital or acquired vascular malformations of the lymphatics, known as lymphatic malformations (LM), are characteristically cystic, fluid-filled collections surrounded by lymphatic endothelium and connective tissue [41]. LM can be associated with pediatric syndromes, like Klippel-Trenaunay, Noonan, Proteus, and Turners or may occur in isolation. LM may be merely uncomfortable and cosmetically displeasing, but depending on their relation to normal anatomical structures, can also have more severe consequences. Nearly three-quarters of patients with LM that involve the head and neck can compromise the airway [42] and become life-threatening, necessitating endotracheal intubation or tracheostomy. Excision, laser ablation, and sclerotherapy have been the mainstays of surgical interventions [42,43]; however, recent results from a Phase 2 pediatric and adult trial (NCT00975819) on the treatment of complex vascular anomalies [44] as well as from two smaller series [45,46], have all suggested benefit with sirolimus (rapamycin). Additionally, a French pediatric Phase 2 trial (NCT03243019) is set to begin in March 2018 to further assess the efficacy of rapamycin in the treatment of cervicofacial LM.

Lymphatic Dysfunction and Multiorgan Dysfunction Syndrome

As noted above, an essential function of the lymphatic vasculature is to participate in immune trafficking and surveillance. Inflammatory states, such as during critical illness, can lead to structural and functional alterations of the lymphatics [47]. For example, in a rodent model of ileitis, Wu et al demonstrated that mesenteric lymphatic vessels were dilated, with impaired contractility [48].

In recent years, the role of the gastrointestinal tract and its associated lymphatic network in mediating critical illness has become much better appreciated [49]. Deitch and his group hypothesized that toxins released by the mesentery after an ischemic insult could bypass the portal circulation and be directly transported by the gut lymphatics to distant organs, resulting in dissemination of tissue injury [50]. Specifically, severe inflammatory states such as acute pancreatitis, can lead to systemic inflammatory response syndrome (SIRS) and multiorgan dysfunction; this most frequently includes severe lung injury and respiratory failure [51]. Interestingly, in a rat model of trauma/hemorrhagic shock, ligation of the efferent mesenteric lymphatics protected the lungs from injury [50]. This benefit has been demonstrated in dogs and primates as well. The results in humans have been more equivocal [52]; these therapies, as for the treatment of chylothorax, have involved occlusion or diversion of the lymphatics, but only after the onset of lung injury, thus limiting potential benefit. Perhaps not too surprisingly, what's old is new again [53] – Cole et al reported on the benefits of a lympho-venous graft to treat right heart failure in a canine model of tricuspid regurgitation and pulmonic stenosis, in 1967 [54]!

Future Promise and Conclusions

While we very much appreciate that interventions such as ligation or embolization that necessarily obliterate vital lymphatic structures, like the thoracic duct or mesenteric lymphatics, are usually only offered in a desperate attempt to try and save the lives of

critically ill patients, it must not be overlooked that these structures are fundamental to the normal and essential functioning of the lymphatic vasculature. Our hope is that as our understanding of normal lymphatic biology continues to advance, we will be able to develop novel strategies to support and augment lymphatic function during critical illness and through convalescence.

To this end, analysis of altered microRNA [55] and proteomic [56] signatures in the mesenteric lymph under conditions of severe systemic inflammation may identify just such promising therapeutic targets. Similarly, specific inhibition of pro-inflammatory cytokines and other inflammatory mediators may prove beneficial in supporting lymphatic function through critical illness. Indeed, inhibition of inducible nitric oxide synthase (iNOS) blunts the inflammatory response associated with burn injury-induced multi-organ dysfunction, decreases pulmonary vascular permeability, normalizes pulmonary lymph flow, and preserves lung function [57]. Alternatively, inhibition of inflammation-mediated lymphangiogenesis using inhibitory antibodies against vascular endothelial growth factor receptor 3 (VEGFR3), has shown benefit in limiting immune rejection following kidney [58,59], heart [60] and corneal transplant.

An expanding body of literature indicates that lymphatic vessel capacitance and pumping primarily dictate lymphatic function under normal physiologic conditions [61–70], and that endothelial nitric oxide (NO) signaling is an important modulator of lymphatic pump activity and lymph flow [64,67,71–75]. However, this has not translated into effective therapies in the ICU. For example, in the setting of severe lung injury and acute respiratory distress syndrome, where supporting pulmonary lymphatic function with inhaled NO would seem to hold great promise, it has not shown any mortality benefit [76] and may cause harm [77].

Perhaps one of the more exciting publications in the last year demonstrated that in a mouse model of experimental lymphedema, targeted pharmacologic inhibition of leukotriene B4 restored lymphatic vessel architecture, improved lymphatic function, and decreased lymphedema [78]. This drug, ubenimex, is currently in a Phase II clinical trial for safety, tolerability, and efficacy (NCT02700529) in patients with lower extremity lymphedema.

Finally, the accelerating field of glymphatics and the recent discovery of lymphatic networks in the meninges of the central nervous system [5,6] could have fundamental implications for how we evaluate the neurologically compromised patient in the ICU, including those with ICU delirium, neuroinflammatory and neurodegenerative diseases, and traumatic brain injury in the critically ill child [79].

- The role of the lymphatic system in critical illness is not well understood, but it likely plays a fundamental role in disease severity and progression in everything from severe systemic inflammatory states to respiratory failure.
- The mainstay of current therapies for congenital and acquired lymphatic abnormalities involves non-specific medical management or surgical intervention to obstruct or divert lymphatic flow.

➤ As our understanding of the signaling pathways that regulate normal lymphatic biology improves, novel avenues of therapy may be directed toward supporting and optimizing lymphatic function during critical illness.

Acknowledgments

We thank Jeffrey Fineman and the members of the Fineman Lab, as well as grant support (R01HL133034, SAD) from the National Institutes of Health.

References

1. Dubberke, CM., Bush, RL. Venous and lymphatic disease: A historical review. In: Gloviczki, P., editor. Handbook of Venous and Lymphatic Disorders: Guidelines of the American Venous Forum. 4th. CRC Press; 2017. p. 13
2. Crivellato E, Travan L, Ribatti D. The Hippocratic treatise ‘On glands’: the first document on lymphoid tissue and lymph nodes. *Leukemia*. 2007; 21:591–592. [PubMed: 17375122]
- 3*. Aspelund A, Robciuc MR, Karaman S, Makinen T, Alitalo K. Lymphatic System in Cardiovascular Medicine. *Circ Res*. 2016; 118:515–530. Comprehensive and most current review on the lymphatic system, with a focus on cardiovascular biology and pathophysiology. [PubMed: 26846644]
4. Butler MG, Isogai S, Weinstein BM. Lymphatic development. *Birth Defects Res C Embryo Today*. 2009; 87:222–231. [PubMed: 19750516]
5. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, et al. Structural and functional features of central nervous system lymphatic vessels. *Nature*. 2015; 523:337–341. [PubMed: 26030524]
6. Aspelund A, Antila S, Proulx ST, Karlson TV, Karaman S, Detmar M, Wiig H, Alitalo K. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. *J Exp Med*. 2015; 212:991–999. [PubMed: 26077718]
7. Louveau A, Harris TH, Kipnis J. Revisiting the Mechanisms of CNS Immune Privilege. *Trends Immunol*. 2015; 36:569–577. [PubMed: 26431936]
8. Schulte-Merker S, Sabine A, Petrova TV. Lymphatic vascular morphogenesis in development, physiology, and disease. *The Journal of Cell Biology*. 2011; 193:607–618. [PubMed: 21576390]
9. Francois M, Harvey NL, Hogan BM. The transcriptional control of lymphatic vascular development. *Physiology*. 2011; 26:146–155. [PubMed: 21670161]
10. Alitalo K. The lymphatic vasculature in disease. *Nat Med*. 2011; 17:1371–1380. [PubMed: 22064427]
11. Mortimer PS, Rockson SG. New developments in clinical aspects of lymphatic disease. *J Clin Invest*. 2014; 124:915–921. [PubMed: 24590276]
12. Yang Y, Oliver G. Development of the mammalian lymphatic vasculature. *J Clin Invest*. 2014; 124:888–897. [PubMed: 24590273]
13. Burger NB, Bekker MN, de Groot CJ, Christoffels VM, Haak MC. Why increased nuchal translucency is associated with congenital heart disease: a systematic review on genetic mechanisms. *Prenat Diagn*. 2015; 35:517–528. [PubMed: 25728762]
14. Rychik J, Rome JJ, Collins MH, DeCampi WM, Spray TL. The hypoplastic left heart syndrome with intact atrial septum: atrial morphology, pulmonary vascular histopathology and outcome. *Journal of the American College of Cardiology*. 1999; 34:554–560. [PubMed: 10440172]
15. Moerman PL, Van Dijk H, Lauweryns JM, Eggermont E, Van der Hauwaert LG. Premature closure of the foramen ovale and congenital pulmonary cystic lymphangiectasis in aortic valve atresia or in severe aortic valve stenosis. *Am J Cardiol*. 1986; 57:703–705. [PubMed: 3953463]
16. Datar SA, Johnson EG, Oishi PE, Johengen M, Tang E, Aramburo A, Barton J, Kuo HC, Bennett S, Xoinis K, et al. Altered lymphatics in an ovine model of congenital heart disease with increased pulmonary blood flow. *American journal of physiology Lung cellular and molecular physiology*. 2012; 302:L530–540. [PubMed: 22207591]

17. Tutor JD. Chylothorax in infants and children. *Pediatrics*. 2014; 133:722–733. [PubMed: 24685960]
18. Downie L, Sasi A, Malhotra A. Congenital chylothorax: associations and neonatal outcomes. *J Paediatr Child Health*. 2014; 50:234–238. [PubMed: 24372911]
19. Zuluaga MT. Chylothorax after surgery for congenital heart disease. *Curr Opin Pediatr*. 2012; 24:291–294. [PubMed: 22498675]
20. Mery CM, Moffett BS, Khan MS, Zhang W, Guzman-Pruneda FA, Fraser CD Jr, Cabrera AG: Incidence and treatment of chylothorax after cardiac surgery in children: analysis of a large multi-institution database. *J Thorac Cardiovasc Surg*. 2014; 147:678–686 e671. discussion 685-676. [PubMed: 24246545]
21. Czobor NR, Roth G, Prodan Z, Lex DJ, Sapi E, Ablonczy L, Gergely M, Szekely EA, Gal J, Szekely A. Chylothorax after pediatric cardiac surgery complicates short-term but not long-term outcomes-a propensity matched analysis. *J Thorac Dis*. 2017; 9:2466–2475. [PubMed: 28932552]
22. Light, RW. 26: Chylothorax and Pseudochylothorax. In: Wolters Kluwer Lippincott Williams & Wilkins. , editor. *Pleural Diseases*. 2013.
23. Faul JL, Berry GJ, Colby TV, Ruoss SJ, Walter MB, Rosen GD, Raffin TA. Thoracic lymphangiomas, lymphangiectasis, lymphangiomatosis, and lymphatic dysplasia syndrome. *Am J Respir Crit Care Med*. 2000; 161:1037–1046. [PubMed: 10712360]
24. Dori Y, Zviman MM, Itkin M. Dynamic contrast-enhanced MR lymphangiography: feasibility study in swine. *Radiology*. 2014; 273:410–416. [PubMed: 24988434]
25. Krishnamurthy R, Hernandez A, Kavuk S, Annam A, Pimpalwar S. Imaging the central conducting lymphatics: initial experience with dynamic MR lymphangiography. *Radiology*. 2015; 274:871–878. [PubMed: 25325323]
- 26*. Savla JJ, Itkin M, Rossano JW, Dori Y. Post-Operative Chylothorax in Patients With Congenital Heart Disease. *J Am Coll Cardiol*. 2017; 69:2410–2422. Authors used dynamic contrast-enhanced magnetic resonance lymphangiography and intranodal lymphangiography to determine the mechanism of chylothorax in patients following cardiac surgery, and successfully treated them with embolization of the thoracic duct. [PubMed: 28494978]
27. Chen E, Itkin M. Thoracic duct embolization for chylous leaks. *Semin Intervent Radiol*. 2011; 28:63–74. [PubMed: 22379277]
28. Itkin M, Kucharczuk JC, Kwak A, Trerotola SO, Kaiser LR. Nonoperative thoracic duct embolization for traumatic thoracic duct leak: experience in 109 patients. *J Thorac Cardiovasc Surg*. 2010; 139:584–589. discussion 589-590. [PubMed: 20042200]
29. Church JT, Antunez AG, Dean A, Matusko N, Deatrick KB, Attar MA, Gadepalli SK. Evidence-based management of chylothorax in infants. *J Pediatr Surg*. 2017; 52:907–912. [PubMed: 28342580]
30. Caverly L, Rausch CM, da Cruz E, Kaufman J. Octreotide treatment of chylothorax in pediatric patients following cardiothoracic surgery. *Congenit Heart Dis*. 2010; 5:573–578. [PubMed: 21106017]
31. Ozeki M, Kanda K, Kawamoto N, Ohnishi H, Fujino A, Hirayama M, Kato Z, Azuma E, Fukao T, Kondo N. Propranolol as an alternative treatment option for pediatric lymphatic malformation. *Tohoku J Exp Med*. 2013; 229:61–66. [PubMed: 23257321]
32. Reinglas J, Ramphal R, Bromwich M. The successful management of diffuse lymphangiomatosis using sirolimus: a case report. *Laryngoscope*. 2011; 121:1851–1854. [PubMed: 22024836]
33. Malleske DT, Yoder BA. Congenital chylothorax treated with oral sildenafil: a case report and review of the literature. *J Perinatol*. 2015; 35:384–386. [PubMed: 25917021]
34. Caruthers RL, Kempa M, Loo A, Gulbransen E, Kelly E, Erickson SR, Hirsch JC, Schumacher KR, Stringer KA. Demographic characteristics and estimated prevalence of Fontan-associated plastic bronchitis. *Pediatr Cardiol*. 2013; 34:256–261. [PubMed: 22797520]
- 35*. Dori Y, Keller MS, Rome JJ, Gillespie MJ, Glatz AC, Dodds K, Goldberg DJ, Goldfarb S, Rychik J, Itkin M. Percutaneous Lymphatic Embolization of Abnormal Pulmonary Lymphatic Flow as Treatment of Plastic Bronchitis in Patients With Congenital Heart Disease. *Circulation*. 2016; 133:1160–1170. Single center retrospective experience on the successful treatment of

patients with congenital heart disease and plastic bronchitis using percutaneous lymphatic embolization. [PubMed: 26864093]

36. Wilson J, Russell J, Williams W, Benson L. Fenestration of the Fontan circuit as treatment for plastic bronchitis. *Pediatr Cardiol.* 2005; 26:717–719. [PubMed: 16132280]
37. Laubisch JE, Green DM, Mogayzel PJ, Reid Thompson W. Treatment of plastic bronchitis by orthotopic heart transplantation. *Pediatr Cardiol.* 2011; 32:1193–1195. [PubMed: 21479821]
38. Onoue Y, Adachi Y, Ichida F, Miyawaki T. Effective use of corticosteroid in a child with life-threatening plastic bronchitis after Fontan operation. *Pediatr Int.* 2003; 45:107–109. [PubMed: 12654082]
39. Heath L, Ling S, Racz J, Mane G, Schmidt L, Myers JL, Tsai WC, Caruthers RL, Hirsch JC, Stringer KA. Prospective, longitudinal study of plastic bronchitis cast pathology and responsiveness to tissue plasminogen activator. *Pediatr Cardiol.* 2011; 32:1182–1189. [PubMed: 21786171]
40. Haseyama K, Satomi G, Yasukochi S, Matsui H, Harada Y, Uchita S. Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome. *J Thorac Cardiovasc Surg.* 2006; 132:1232–1233. [PubMed: 17059953]
41. Blei F. Congenital lymphatic malformations. *Ann N Y Acad Sci.* 2008; 1131:185–194. [PubMed: 18519970]
42. Klosterman T, O TM. The Management of Vascular Malformations of the Airway: Natural History, Investigations, Medical, Surgical and Radiological Management. *Otolaryngol Clin North Am.* 2018; 51:213–223. [PubMed: 29217064]
43. Ghaffarpour N, Burgos CM, Wester T. Surgical excision is the treatment of choice for cervical lymphatic malformations with mediastinal expansion. *J Pediatr Surg.* 2017
- 44*. Adams DM, Trenor CC 3rd, Hammill AM, Vinks AA, Patel MN, Chaudry G, Wentzel MS, Mobberley-Schuman PS, Campbell LM, Brookbank C, et al. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. *Pediatrics.* 2016; 137:e20153257. Results of a Phase II clinical trial assessing safety and efficacy of sirolimus in the treatment of complicated vascular anomalies. [PubMed: 26783326]
45. Alemi AS, Rosbe KW, Chan DK, Meyer AK. Airway response to sirolimus therapy for the treatment of complex pediatric lymphatic malformations. *Int J Pediatr Otorhinolaryngol.* 2015; 79:2466–2469. [PubMed: 26549380]
46. Strychowsky JE, Rahbar R, O'Hare MJ, Irace AL, Padua H, Trenor CC 3rd. Sirolimus as treatment for 19 patients with refractory cervicofacial lymphatic malformation. *Laryngoscope.* 2018; 128:269–276. [PubMed: 28782106]
47. Liao S, von der Weid PY. Inflammation-induced lymphangiogenesis and lymphatic dysfunction. *Angiogenesis.* 2014; 17:325–334. [PubMed: 24449090]
48. Wu TF, Carati CJ, Macnaughton WK, von der Weid PY. Contractile activity of lymphatic vessels is altered in the TNBS model of guinea pig ileitis. *Am J Physiol Gastrointest Liver Physiol.* 2006; 291:G566–574. [PubMed: 16675748]
49. Mittal R, Coopersmith CM. Redefining the gut as the motor of critical illness. *Trends Mol Med.* 2014; 20:214–223. [PubMed: 24055446]
50. Deitch EA. Gut lymph and lymphatics: a source of factors leading to organ injury and dysfunction. *Annals of the New York Academy of Sciences.* 2010; 1207:E103–E111. [PubMed: 20961300]
51. Landahl P, Ansari D, Andersson R. Severe Acute Pancreatitis: Gut Barrier Failure, Systemic Inflammatory Response, Acute Lung Injury, and the Role of the Mesenteric Lymph. *Surg Infect (Larchmt).* 2015; 16:651–656. [PubMed: 26237406]
52. Dugernier T, Reynaert MS, Deby-Dupont G, Roeseler JJ, Carlier M, Squifflet JP, Deby C, Pincemail J, Lamy M, De Maeght S, et al. Prospective evaluation of thoracic-duct drainage in the treatment of respiratory failure complicating severe acute pancreatitis. *Intensive Care Med.* 1989; 15:372–378. [PubMed: 2553789]
53. Basta MN, Gao LL, Wu LC. Operative treatment of peripheral lymphedema: a systematic meta-analysis of the efficacy and safety of lymphovenous microsurgery and tissue transplantation. *Plast Reconstr Surg.* 2014; 133:905–913. [PubMed: 24352208]

54. Cole WR, Witte MH, Kash SL, Rodger M, Bleisch WR, Muelheims GH. Thoracic duct-to-pulmonary vein shunt in the treatment of experimental right heart failure. *Circulation*. 1967; 36:539–543. [PubMed: 6041867]
55. Blenkiron C, Askelund KJ, Shanbhag ST, Chakraborty M, Petrov MS, Delahunt B, Windsor JA, Phillips AR. MicroRNAs in mesenteric lymph and plasma during acute pancreatitis. *Ann Surg*. 2014; 260:341–347. [PubMed: 24509209]
56. Mittal A, Phillips AR, Middleditch M, Ruggiero K, Loveday B, Delahunt B, Cooper GJ, Windsor JA. The proteome of mesenteric lymph during acute pancreatitis and implications for treatment. *JOP*. 2009; 10:130–142. [PubMed: 19287105]
57. Enkhbaatar P, Murakami K, Shimoda K, Mizutani A, Traber L, Phillips GB, Parkinson JF, Cox R, Hawkins H, Herndon D, et al. The inducible nitric oxide synthase inhibitor BBS-2 prevents acute lung injury in sheep after burn and smoke inhalation injury. *Am J Respir Crit Care Med*. 2003; 167:1021–1026. [PubMed: 12663341]
58. Kerjaschki D, Regele HM, Moosberger I, Nagy-Bojarski K, Watschinger B, Soleiman A, Birner P, Krieger S, Hovorka A, Silberhumer G, et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. *J Am Soc Nephrol*. 2004; 15:603–612. [PubMed: 14978162]
59. Kerjaschki D, Huttary N, Raab I, Regele H, Bojarski-Nagy K, Bartel G, Krober SM, Greinix H, Rosenmaier A, Karlhofer F, et al. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. *Nat Med*. 2006; 12:230–234. [PubMed: 16415878]
60. Nykanen AI, Sandelin H, Krebs R, Keranen MA, Tuuminen R, Karpanen T, Wu Y, Pytowski B, Koskinen PK, Yla-Herttuala S, et al. Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts. *Circulation*. 2010; 121:1413–1422. [PubMed: 20231530]
61. Davis MJ, Davis AM, Ku CW, Gashev AA. Myogenic constriction and dilation of isolated lymphatic vessels. *American journal of physiology Heart and circulatory physiology*. 2009; 296:H293–302. [PubMed: 19028793]
62. Gashev AA. Lymphatic vessels: pressure- and flow-dependent regulatory reactions. *Annals of the New York Academy of Sciences*. 2008; 1131:100–109. [PubMed: 18519963]
63. Gashev AA, Davis MJ, Delp MD, Zawieja DC. Regional variations of contractile activity in isolated rat lymphatics. *Microcirculation*. 2004; 11:477–492. [PubMed: 15371129]
64. Gashev AA, Davis MJ, Zawieja DC. Inhibition of the active lymph pump by flow in rat mesenteric lymphatics and thoracic duct. *J Physiol (Lond)*. 2002; 540:1023–1037. [PubMed: 11986387]
65. Gashev AA, Delp MD, Zawieja DC. Inhibition of active lymph pump by simulated microgravity in rats. *Am J Physiol Heart Circ Physiol*. 2006; 290:H2295–2308. [PubMed: 16399874]
66. Gasheva OY, Gashev AA, Zawieja DC. Cyclic guanosine monophosphate and the dependent protein kinase regulate lymphatic contractility in rat thoracic duct. *J Physiol*. 2013; 591:4549–4565. [PubMed: 23836689]
67. Gasheva OY, Zawieja DC, Gashev AA. Contraction-initiated NO-dependent lymphatic relaxation: a self-regulatory mechanism in rat thoracic duct. *J Physiol (Lond)*. 2006; 575:821–832. [PubMed: 16809357]
68. Scallan JP, Wolpers JH, Muthuchamy M, Zawieja DC, Gashev AA, Davis MJ. Independent and interactive effects of preload and afterload on the pump function of the isolated lymphangion. *American journal of physiology Heart and circulatory physiology*. 2012; 303:H809–824. [PubMed: 22865389]
69. Davis MJ, Scallan JP, Wolpers JH, Muthuchamy M, Gashev AA, Zawieja DC. Intrinsic increase in lymphangion muscle contractility in response to elevated afterload. *American journal of physiology Heart and circulatory physiology*. 2012; 303:H795–808. [PubMed: 22886407]
70. Zawieja D. Contractile physiology of lymphatics. *Lymphatic Research And Biology*. 2009; 7:87–96. [PubMed: 19534632]
71. Tsunemoto H, Ikomi F, Ohhashi T. Flow-mediated release of nitric oxide from lymphatic endothelial cells of pressurized canine thoracic duct. *The Japanese journal of physiology*. 2003; 53:157–163. [PubMed: 14529576]

72. Bohlen HG, Wang W, Gashev A, Gasheva O, Zawieja D. Phasic contractions of rat mesenteric lymphatics increase basal and phasic nitric oxide generation in vivo. *Am J Physiol Heart Circ Physiol*. 2009; 297:H1319–1328. [PubMed: 19666850]
73. Hagendoorn J, Padera TP, Kashiwagi S, Isaka N, Noda F, Lin MI, Huang PL, Sessa WC, Fukumura D, Jain RK. Endothelial nitric oxide synthase regulates microlymphatic flow via collecting lymphatics. *Circ Res*. 2004; 95:204–209. [PubMed: 15192027]
74. Datar SA, Gong W, He Y, Johengen M, Kameny RJ, Raff GW, Maltepe E, Oishi PE, Fineman JR. Disrupted NOS signaling in lymphatic endothelial cells exposed to chronically increased pulmonary lymph flow. *Am J Physiol Heart Circ Physiol*. 2016; 311:H137–145. [PubMed: 27199125]
75. Datar SA, Oishi PE, Gong W, Bennett SH, Sun CE, Johengen M, Maki J, Johnson RC, Raff GW, Fineman JR. Altered reactivity and nitric oxide signaling in the isolated thoracic duct from an ovine model of congenital heart disease with increased pulmonary blood flow. *Am J Physiol Heart Circ Physiol*. 2014; 306:H954–962. [PubMed: 24531811]
76. Calfee CS, Matthay MA. Nonventilatory treatments for acute lung injury and ARDS. *Chest*. 2007; 131:913–920. [PubMed: 17356114]
77. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. *BMJ*. 2007; 334:779. [PubMed: 17383982]
- 78**. Tian W, Rockson SG, Jiang X, Kim J, Begaye A, Shuffle EM, Tu AB, Cribb M, Nepiyushchikh Z, Feroze AH, et al. Leukotriene B4 antagonism ameliorates experimental lymphedema. *Sci Transl Med*. 2017; 9 Authors show that pharmacologic inhibition of leukotriene B4 in an experimental mouse model of lymphedema restores lymphatic architecture, improves lymphatic function, and decreases lymphedema. These results have directly translated into a Phase II clinical trial.
79. Plog BA, Nedergaard M. The Glymphatic System in Central Nervous System Health and Disease: Past, Present, and Future. *Annu Rev Pathol*. 2018; 13:379–394. [PubMed: 29195051]